ホームページ GPCR & G Protein Glucagon Receptor

Glucagon Receptor

亜型選択性的な製品

Glucagon Receptor製品

  • All (20)
  • Glucagon Receptor拮抗剤(1)
  • Glucagon Receptor作動薬(8)
  • Glucagon Receptorモジュレータ(1)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S8256 Liraglutide Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.
J Immunother Cancer, 2024, 12(3)e008431
J Transl Med, 2024, 22(1):954
Front Endocrinol (Lausanne), 2024, 15:1395028
S9852New Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
E1173 V-0219 V-0219 is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R), can be used for obesity-associated diabetes research.
S3734 Albiglutide Fragment Albiglutide fragment is one copy of a 30-amino-acid sequence of modified human GLP-1 (fragment 7-36).
S0555 Adomeglivant Adomeglivant (LY2409021) is a potent and selective antagonist of glucagon receptor that is used as a chronic treatment for type 2 diabetes.
S9697 Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Nat Commun, 2024, 15(1):7991
S8517 Lixisenatide Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
S9935 Teduglutide Teduglutide (ALX-0600, Gattex, Revestive, TAK 633) is an analogue of human glucagon-like peptide-2 (GLP-2) and binds to the GLP-2 receptors. Teduglutide prolongs the intestinotrophic properties of GLP-2 in animal models.
E4779New DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. DMB attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
S9307 Shanzhiside methyl ester Shanzhiside methylester is a principle effective iridoid glycoside of L. rotata and serves as a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
P1230New Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.
S9851 Danuglipron (PF-06882961) Danuglipron (PF-06882961), a non-peptide agonist, activates the canonical G protein signaling activity only in the Glucagon-like peptide-1 (GLP-1) receptor with Trp33ECD.
S8256 Liraglutide Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.
J Immunother Cancer, 2024, 12(3)e008431
J Transl Med, 2024, 22(1):954
Front Endocrinol (Lausanne), 2024, 15:1395028
S9852New Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
S9697 Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Nat Commun, 2024, 15(1):7991
S8517 Lixisenatide Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
E4779New DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. DMB attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
S9307 Shanzhiside methyl ester Shanzhiside methylester is a principle effective iridoid glycoside of L. rotata and serves as a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
P1230New Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.
S9851 Danuglipron (PF-06882961) Danuglipron (PF-06882961), a non-peptide agonist, activates the canonical G protein signaling activity only in the Glucagon-like peptide-1 (GLP-1) receptor with Trp33ECD.
S0555 Adomeglivant Adomeglivant (LY2409021) is a potent and selective antagonist of glucagon receptor that is used as a chronic treatment for type 2 diabetes.
S8256 Liraglutide Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.
J Immunother Cancer, 2024, 12(3)e008431
J Transl Med, 2024, 22(1):954
Front Endocrinol (Lausanne), 2024, 15:1395028
S9852New Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
S9697 Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Nat Commun, 2024, 15(1):7991
S8517 Lixisenatide Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
E4779New DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. DMB attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
S9307 Shanzhiside methyl ester Shanzhiside methylester is a principle effective iridoid glycoside of L. rotata and serves as a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
P1230New Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.
S9851 Danuglipron (PF-06882961) Danuglipron (PF-06882961), a non-peptide agonist, activates the canonical G protein signaling activity only in the Glucagon-like peptide-1 (GLP-1) receptor with Trp33ECD.
E1173 V-0219 V-0219 is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R), can be used for obesity-associated diabetes research.
S9852New Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
E4779New DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. DMB attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
P1230New Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.
S9852New Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
E4779New DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. DMB attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
P1230New Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.

Glucagon Receptor阻害剤の選択性比較

Tags: Glucagon Receptor antagonist | Glucagon Receptor agonist | Glucagon Receptor Inhibition| Glucagon Receptor Activation| Glucagon Receptor antagonist | Glucagon Receptor agonist | Glucagon Receptor Activity